News
Invitation to First-Half 2026 webcast - Thursday 27 August 2026
Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]
Oncoinvent ASA: Grant of share options to member of the Board following AGM
Oncoinvent ASA: Minutes from Annual General Meeting
Oncoinvent ASA: Share capital decrease completed
Oncoinvent presents corporate update in live webcast
Oncoinvent ASA: Notice of Annual General Meeting
Oncoinvent ASA: Invitation to business update Wednesday 29 April 2026
